FOLD · As filed with the SEC
Amicus Therapeutics cash flow statement, by fiscal year
The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||
| Net loss | (27,110) | (56,106) | (151,584) | (236,568) | (250,460) | (276,852) | (356,388) | (348,995) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Amortization of debt discount and deferred financing | 2,570 | 2,262 | 2,616 | 2,634 | 2,490 | 1,794 | 2,546 | 10,976 |
| Depreciation | — | — | — | — | — | — | — | 4,216 |
| Depreciation and amortization | 7,460 | 8,547 | 7,873 | 5,342 | 6,209 | 8,846 | 4,775 | — |
| Stock-based compensation | 87,410 | 84,905 | 86,077 | 76,512 | 57,838 | 49,151 | 44,430 | 29,260 |
| Restructuring charges | — | — | — | — | — | — | — | 0 |
| Loss on exchange of convertible notes | — | — | — | — | 0 | 0 | — | — |
| Loss on extinguishment of debt | 0 | 0 | 13,933 | 0 | 257 | 7,276 | 40,624 | 0 |
| Change in fair value of derivatives | — | — | — | — | — | 0 | 0 | 2,739 |
| Non-cash changes in the fair value of contingent consideration payable | 0 | 0 | 2,583 | 1,078 | 6,514 | 3,144 | 3,297 | 3,300 |
| Charges to research expense for stock issued in asset acquisition | — | — | — | — | — | — | — | 0 |
| Foreign currency remeasurement loss | 3,586 | 16,234 | 19,613 | 6,121 | 3,565 | 5,471 | 254 | 3,217 |
| Non-cash deferred taxes | — | — | — | — | — | (155) | (1,415) | 0 |
| (Gain) loss on disposal of assets | — | — | — | — | — | — | — | 59 |
| Loss on impairment | — | — | — | — | — | — | 0 | 0 |
| Non-cash deferred taxes | 0 | 0 | (4,939) | 9 | 34 | — | — | — |
| Other | — | — | — | — | 0 | 99 | (149) | — |
| Asset impairment charges and other write-offs | (1,138) | 9,210 | 2,727 | 18,177 | — | — | — | — |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | (5,860) | (19,484) | (20,108) | (17,330) | (8,189) | (11,219) | (11,114) | (13,294) |
| Inventories | (111,483) | (73,652) | (44,614) | (5,343) | (7,790) | (4,639) | (5,114) | (4,205) |
| Prepaid expenses and other current assets | (1,382) | 13,961 | (8,062) | (6,194) | (5,919) | (8,766) | (3,287) | 2,488 |
| Other non-current assets | — | — | — | — | — | — | — | (1,039) |
| Accounts payable, accrued expenses, and other current liabilities | 82,777 | (16,520) | 49,195 | (6,377) | 7,430 | (10,610) | 46,742 | 17,115 |
| Other non-current assets and liabilities | (3,685) | (3,248) | (3,054) | (4,636) | (2,617) | 4,420 | (10,117) | 458 |
| Deferred reimbursements | — | — | — | — | (1,500) | (1,250) | (5,500) | (6,250) |
| Payment of contingent consideration | 0 | 0 | (21,347) | 0 | (10,353) | — | — | — |
| Net cash provided by (used in) operating activities | 33,145 | (33,891) | (69,091) | (166,575) | (202,491) | (233,290) | (250,416) | (299,955) |
| Investing activities | ||||||||
| Sale and redemption of marketable securities | 51,269 | 117,779 | 197,227 | 335,926 | 424,043 | 354,826 | 499,047 | 463,502 |
| Purchases of marketable securities | (94,405) | (114,786) | (91,723) | (243,255) | (341,398) | (365,178) | (383,882) | (578,394) |
| Capital expenditures | (3,296) | (3,553) | (7,440) | (3,766) | (3,884) | (3,227) | (20,012) | (6,308) |
| Proceeds from sale of assets | — | 0 | 0 | 3,411 | — | — | — | — |
| Net cash (used in) provided by investing activities | (46,432) | (560) | 98,064 | 92,316 | 78,761 | (13,579) | 95,153 | (121,200) |
| Financing activities | ||||||||
| Proceeds from issuance of common stock from equity financing and pre-funded warrants, net of issuance costs | — | — | — | 0 | 199,750 | — | — | — |
| Proceeds from issuance of common stock, net of issuance costs | — | — | — | — | 0 | 0 | 188,994 | 294,584 |
| Payments of secured loan agreement | — | — | — | — | — | — | — | 0 |
| Proceeds from the issuance of shares in connection with at-the-market offering, net of issuance costs | 0 | 19,566 | 63,108 | — | — | — | — | — |
| Proceeds from equity financing, net of issuance costs | 0 | 0 | 29,827 | — | — | — | — | — |
| Withholding taxes paid on vested restricted stock units | (18,323) | (22,025) | (17,920) | (11,490) | — | — | — | — |
| Proceeds from stock options exercised, net | 19,205 | 7,677 | 10,261 | 4,310 | 10,228 | 42,282 | 11,476 | 9,144 |
| Proceeds from warrants exercised, net | 0 | 0 | 12 | 0 | 19,230 | 0 | 812 | 3,617 |
| Payment of contingent consideration | — | — | — | — | — | — | 0 | 0 |
| Proceeds from issuance of convertible notes, net of issuance costs | — | — | — | — | — | — | — | 0 |
| Premiums paid for Capped Call Confirmations | — | — | — | — | — | — | — | 0 |
| Proceeds from loan agreements, net of issuance costs | — | — | — | — | — | — | 0 | 146,596 |
| Payment of long-term debt | 0 | 0 | (408,043) | 0 | 0 | (155,249) | — | — |
| Proceeds from long-term debt, net of issuance costs | 0 | 0 | 387,360 | 0 | 0 | 385,929 | — | — |
| Payment of contingent consideration | 0 | 0 | (2,653) | 0 | (1,647) | — | — | — |
| Payment of finance leases | (272) | (97) | (275) | (283) | (479) | (76) | (420) | — |
| Payment of finance leases | — | — | — | — | — | — | — | (334) |
| Payments of employee withholding taxes related to restricted stock unit vesting | — | — | — | — | (15,009) | (10,028) | (3,235) | (2,832) |
| Proceeds from termination of capped call confirmations | — | — | — | — | 0 | 0 | 19,875 | — |
| Net cash provided by financing activities | 610 | 5,121 | 61,677 | (7,463) | 212,073 | 262,858 | 217,502 | 450,775 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 13,277 | (4,031) | 6,312 | (14,619) | (5,049) | 3,830 | 1,729 | 1,518 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 600 | (33,361) | 96,962 | (96,341) | 83,294 | 19,819 | 63,968 | 31,138 |
| Cash, cash equivalents, and restricted cash at the beginning of the year | 216,716 | 250,077 | 153,115 | 249,456 | 166,162 | 146,343 | 82,375 | 51,237 |
| Cash, cash equivalents, and restricted cash at the end of the year | 217,316 | 216,716 | 250,077 | 153,115 | 249,456 | 166,162 | 146,343 | 82,375 |
| Supplemental disclosures of cash flow information | ||||||||
| Tenant improvements paid through lease incentive | — | — | 105 | 0 | 300 | 470 | 19,388 | — |
| Tenant improvements paid through lease incentive | 390 | 315 | — | — | — | — | — | — |
| Cash paid during the period for interest | 43,608 | 58,960 | 36,090 | 34,358 | 30,468 | 24,683 | 16,966 | 7,500 |
| Contingent consideration paid in shares | — | — | — | — | 0 | 0 | 9,316 | 0 |
| Capital expenditures unpaid at the end of period | — | — | — | — | — | — | — | 106 |
| Capital expenditures funded by capital lease borrowings | — | — | — | — | — | — | — | 208 |
| Cashless exercise of warrants | 71 | — | — | — | — | — | — | — |
| Capital expenditures unpaid at the end of period | 73 | 103 | 868 | 1,141 | 1,448 | 985 | 1,865 | — |
| Cash paid for income taxes | 14,894 | 8,214 | 8,525 | 1,609 | 20,032 | 10,371 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.